Tags

Type your tag names separated by a space and hit enter

The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
Viruses. 2021 04 07; 13(4)V

Abstract

A new variant of SARS-CoV-2 B.1.351 lineage (first found in South Africa) has been raising global concern due to its harboring of multiple mutations in the spike that potentially increase transmissibility and yield resistance to neutralizing antibodies. We here tested infectivity and neutralization efficiency of SARS-CoV-2 spike pseudoviruses bearing particular mutations of the receptor-binding domain (RBD) derived either from the Wuhan strains (referred to as D614G or with other sites) or the B.1.351 lineage (referred to as N501Y, K417N, and E484K). The three different pseudoviruses B.1.351 lineage related significantly increased infectivity compared with other mutants that indicated Wuhan strains. Interestingly, K417N and E484K mutations dramatically enhanced cell-cell fusion than N501Y even though their infectivity were similar, suggesting that K417N and E484K mutations harboring SARS-CoV-2 variant might be more transmissible than N501Y mutation containing SARS-CoV-2 variant. We also investigated the efficacy of two different monoclonal antibodies, Casirivimab and Imdevimab that neutralized SARS-CoV-2, against several kinds of pseudoviruses which indicated Wuhan or B.1.351 lineage. Remarkably, Imdevimab effectively neutralized B.1.351 lineage pseudoviruses containing N501Y, K417N, and E484K mutations, while Casirivimab partially affected them. Overall, our results underscore the importance of B.1.351 lineage SARS-CoV-2 in the viral spread and its implication for antibody efficacy.

Authors+Show Affiliations

Department of Biotechnology and Bioinformatics, College of Science and Technology, Korea University, Sejong 30019, Korea.Department of Biotechnology and Bioinformatics, College of Science and Technology, Korea University, Sejong 30019, Korea.Department of Biotechnology and Bioinformatics, College of Science and Technology, Korea University, Sejong 30019, Korea.Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, Korea.Department of Biotechnology and Bioinformatics, College of Science and Technology, Korea University, Sejong 30019, Korea. Department of Lab Medicine, College of Medicine, Korea University, Seoul 02841, Korea.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33917138

Citation

Kim, Yeong Jun, et al. "The Impact On Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus." Viruses, vol. 13, no. 4, 2021.
Kim YJ, Jang US, Soh SM, et al. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus. Viruses. 2021;13(4).
Kim, Y. J., Jang, U. S., Soh, S. M., Lee, J. Y., & Lee, H. R. (2021). The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus. Viruses, 13(4). https://doi.org/10.3390/v13040633
Kim YJ, et al. The Impact On Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus. Viruses. 2021 04 7;13(4) PubMed PMID: 33917138.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus. AU - Kim,Yeong Jun, AU - Jang,Ui Soon, AU - Soh,Sandrine M, AU - Lee,Joo-Youn, AU - Lee,Hye-Ra, Y1 - 2021/04/07/ PY - 2021/03/19/received PY - 2021/04/04/revised PY - 2021/04/05/accepted PY - 2021/4/30/entrez PY - 2021/5/1/pubmed PY - 2021/6/4/medline KW - B.1.351 KW - Casirivimab KW - Imdevimab KW - K417N and E484K mutation of spike KW - SARS-CoV-2 KW - neutralization KW - viral infectivity JF - Viruses JO - Viruses VL - 13 IS - 4 N2 - A new variant of SARS-CoV-2 B.1.351 lineage (first found in South Africa) has been raising global concern due to its harboring of multiple mutations in the spike that potentially increase transmissibility and yield resistance to neutralizing antibodies. We here tested infectivity and neutralization efficiency of SARS-CoV-2 spike pseudoviruses bearing particular mutations of the receptor-binding domain (RBD) derived either from the Wuhan strains (referred to as D614G or with other sites) or the B.1.351 lineage (referred to as N501Y, K417N, and E484K). The three different pseudoviruses B.1.351 lineage related significantly increased infectivity compared with other mutants that indicated Wuhan strains. Interestingly, K417N and E484K mutations dramatically enhanced cell-cell fusion than N501Y even though their infectivity were similar, suggesting that K417N and E484K mutations harboring SARS-CoV-2 variant might be more transmissible than N501Y mutation containing SARS-CoV-2 variant. We also investigated the efficacy of two different monoclonal antibodies, Casirivimab and Imdevimab that neutralized SARS-CoV-2, against several kinds of pseudoviruses which indicated Wuhan or B.1.351 lineage. Remarkably, Imdevimab effectively neutralized B.1.351 lineage pseudoviruses containing N501Y, K417N, and E484K mutations, while Casirivimab partially affected them. Overall, our results underscore the importance of B.1.351 lineage SARS-CoV-2 in the viral spread and its implication for antibody efficacy. SN - 1999-4915 UR - https://www.unboundmedicine.com/medline/citation/33917138/The_Impact_on_Infectivity_and_Neutralization_Efficiency_of_SARS_CoV_2_Lineage_B_1_351_Pseudovirus_ L2 - https://www.mdpi.com/resolver?pii=v13040633 DB - PRIME DP - Unbound Medicine ER -